Jul 20, 2026 07:30AM
Jul 20, 2026 07:30AM
Jun 22, 2026 04:10PM
Jun 22, 2026 04:10PM
Jun 17, 2026 07:30AM
Jun 17, 2026 07:30AM
Jun 3, 2026 07:30AM Dyne Therapeutics completes enrollment in myotonic dystrophy trial
Jun 3, 2026 07:30AM
May 26, 2026 07:31AM
May 26, 2026 07:30AM
May 20, 2026 07:46AM
May 20, 2026 07:46AM
May 11, 2026 07:30AM
May 11, 2026 07:30AM Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Apr 27, 2026 04:34PM
Apr 1, 2026 07:30AM
Mar 9, 2026 12:34PM
Mar 9, 2026 11:45AM
Mar 9, 2026 10:29AM
Mar 9, 2026 05:26AM
Mar 8, 2026 06:01PM Dyne Therapeutics starts phase 3 trial of DM1 treatment
Mar 8, 2026 06:01PM
Mar 8, 2026 06:00PM
Mar 3, 2026 07:22AM
Mar 2, 2026 05:37PM
Mar 2, 2026 02:37PM
Mar 2, 2026 07:30AM
Feb 22, 2026 04:00PM Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
Feb 22, 2026 04:00PM
Jan 20, 2026 07:30AM
Jan 20, 2026 07:30AM
Dec 23, 2025 07:30AM
Dec 23, 2025 07:30AM
Dec 9, 2025 07:40AM
Dec 8, 2025 07:40AM Dyne Therapeutics (DYN) PT Raised to $40 at Raymond James
Dec 8, 2025 06:30AM
Dec 8, 2025 06:30AM
Nov 16, 2025 03:00PM
Nov 5, 2025 04:10PM
Oct 24, 2025 08:29AM
Oct 6, 2025 06:01PM
Oct 6, 2025 06:01PM Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
Oct 2, 2025 04:05PM
Oct 2, 2025 04:05PM
Sep 29, 2025 08:35AM
Sep 29, 2025 08:35AM
Sep 11, 2025 08:18AM
Aug 4, 2025 08:31AM
Aug 4, 2025 07:30AM Dyne Therapeutics receives FDA breakthrough therapy designation for DYNE-251
Aug 4, 2025 07:30AM

326,362 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All